Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Epizyme Inc proposes public offering of common stock


Monday, 3 Feb 2014 06:51am EST 

Epizyme Inc:Commences an underwritten public offering of 4,192,679 shares of its common stock.Says the offering is expected to consist of 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders.Says it will not receive any proceeds from the sale of shares by the selling stockholders.Says it intends to grant the underwriters a 30-day option to purchase up to 628,901 shares of common stock.Says it intends to use proceeds from the offering to fund the company's share of the global development costs of clinical development of EPZ-5676, including the costs of the expansion stage of its ongoing Phase 1 clinical trial of EPZ-5676 in MLL-r adult patients.Says also intent to use for MLL-PTD adult patients and its planned Phase 1b clinical trial of EPZ-5676 in MLL-r pediatric patients.Says to fund research and development to build the company's product platform and advance its pipeline of preclinical product candidates.Says intends to use for working capital and general corporate purposes. 

Company Quote

18.37
0.66 +3.73%
26 Dec 2014